{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T21:10:35Z","timestamp":1784581835817,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-025-04416-w","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T12:03:53Z","timestamp":1764072233000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A case of folinic acid, fluorouracil and oxaliplatin (FOLFOX) chemotherapy regimen associated neurotoxicity and review of literature"],"prefix":"10.1186","volume":"25","author":[{"given":"Juhi","family":"Srivastava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esha Kataria","family":"DO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Sivakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Mullaguri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"issue":"5","key":"4416_CR1","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1158\/1055-9965.EPI-13-1057","volume":"23","author":"P Karimi","year":"2014","unstructured":"Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23(5):700\u201313. https:\/\/doi.org\/10.1158\/1055-9965.EPI-13-1057.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"12","key":"4416_CR2","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1002\/ijc.25516","volume":"127","author":"J Ferlay","year":"2010","unstructured":"Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893\u2013917. https:\/\/doi.org\/10.1002\/ijc.25516.","journal-title":"Int J Cancer."},{"issue":"6","key":"4416_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/MOG.0000000000000475","volume":"34","author":"DJ Ilson","year":"2018","unstructured":"Ilson DH. Advances in the treatment of gastric cancer. Curr Opin Gastroenterol. 2018 Nov;34(6):465-468. doi: 10.1097\/MOG.0000000000000475. PMID: 30303856.https:\/\/doi.org\/10.1097\/MOG.0000000000000475.PMID: 30303856.","journal-title":"Curr Opin Gastroenterol"},{"issue":"4","key":"4416_CR4","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3390\/cancers14041054","volume":"14","author":"S Takei","year":"2022","unstructured":"Takei S, Kawazoe A, Shitara K. The New Era of Immunotherapy in Gastric Cancer. Cancers (Basel). 2022 Feb 18;14(4):1054.https:\/\/doi.org\/10.3390\/cancers14041054. PMID: 35205802; PMCID: PMC8870470.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"4416_CR5","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ana.24951","volume":"81","author":"NP Staff","year":"2017","unstructured":"Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol. 2017;81(6):772\u201381. https:\/\/doi.org\/10.1002\/ana.24951.","journal-title":"Ann Neurol"},{"issue":"12","key":"4416_CR6","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1093\/annonc\/mds208","volume":"23","author":"AA Argyriou","year":"2012","unstructured":"Argyriou AA, Velasco R, Briani C, et al. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. Ann Oncol. 2012;23(12):3116\u201322. https:\/\/doi.org\/10.1093\/annonc\/mds208.","journal-title":"Ann Oncol"},{"issue":"2","key":"4416_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1001\/archneur.1970.00480260061008","volume":"23","author":"H Koenig","year":"1970","unstructured":"Koenig H, Patel A. Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate. Arch Neurol. 1970;23(2):155\u201360. https:\/\/doi.org\/10.1001\/archneur.1970.00480260061008.","journal-title":"Arch Neurol"},{"issue":"4","key":"4416_CR8","first-page":"1531","volume":"34","author":"P Papanastasopoulos","year":"2014","unstructured":"Papanastasopoulos P, Stebbing J. Molecular basis of 5-fluorouracil-related toxicity: lessons from clinical practice. Anticancer Res. 2014;34(4):1531\u20135.","journal-title":"Anticancer Res"},{"issue":"22","key":"4416_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006874","volume":"96","author":"S Mitani","year":"2017","unstructured":"Mitani S, Kadowaki S, Komori A, et al. Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy: a case series and review of the literature. Medicine (Baltimore). 2017;96(22):e6874. https:\/\/doi.org\/10.1097\/MD.0000000000006874.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"4416_CR10","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1177\/19418744211068913","volume":"12","author":"R Jules","year":"2022","unstructured":"Jules R, Thaper A, Foster R, et al. 5-fluorouracil neurotoxicity in the absence of dihydropyrimidine dehydrogenase deficiency case report. Neurohospitalist. 2022;12(2):366\u201370. https:\/\/doi.org\/10.1177\/19418744211068913.","journal-title":"Neurohospitalist"},{"issue":"2","key":"4416_CR11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.4103\/2278-330X.208850","volume":"6","author":"U Batra","year":"2017","unstructured":"Batra U, Koyyala VPB, Jain A, Agrawal C, Maheswari U. Folfox encephalopathy: A rare case series. South Asian J Cancer. 2017;6(2):86\u20137. https:\/\/doi.org\/10.4103\/2278-330X.208850.","journal-title":"South Asian J Cancer"},{"issue":"4","key":"4416_CR12","doi-asserted-by":"publisher","first-page":"e37237","DOI":"10.7759\/cureus.37237","volume":"15","author":"JS Kim","year":"2023","unstructured":"Kim JS, Lio KU, Henderson H, Pourshahid S. A case of acute encephalopathy after the initiation of FOLFOX chemotherapy in a patient with colon cancer. Cureus. 2023;15(4):e37237. https:\/\/doi.org\/10.7759\/cureus.37237. Published 2023 Apr 7.","journal-title":"Cureus"},{"issue":"18","key":"4416_CR13","doi-asserted-by":"publisher","first-page":"4545","DOI":"10.1158\/1078-0432.CCR-16-0638","volume":"22","author":"G Ison","year":"2016","unstructured":"Ison G, Beaver JA, McGuinn WD Jr., et al. FDA approval: uridine triacetate for the treatment of patients following fluorouracil or capecitabine overdose or exhibiting early-onset severe toxicities following administration of these drugs. Clin Cancer Res. 2016;22(18):4545\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0638.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4416_CR14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/cncr.30321","volume":"123","author":"WW Ma","year":"2017","unstructured":"Ma WW, Saif MW, El-Rayes BF, et al. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. Cancer. 2017;123(2):345\u201356. https:\/\/doi.org\/10.1002\/cncr.30321.","journal-title":"Cancer"},{"issue":"12","key":"4416_CR15","doi-asserted-by":"publisher","first-page":"e49898","DOI":"10.7759\/cureus.49898","volume":"15","author":"U Natarajan","year":"2023","unstructured":"Natarajan U, Onyechi A, Ohemeng-Dapaah J. 5-fluorouracil neurotoxicity in a patient with normal dihydropyrimidine dehydrogenase activity. Cureus. 2023;15(12):e49898. https:\/\/doi.org\/10.7759\/cureus.49898. (Published 2023 Dec 4).","journal-title":"Cureus"},{"key":"4416_CR16","doi-asserted-by":"publisher","first-page":"bcr2017222030","DOI":"10.1136\/bcr-2017-222030","volume":"2017","author":"G Acharya","year":"2017","unstructured":"Acharya G, Cruz Carreras MT, Rice TW. 5-FU-induced leukoencephalopathy with reversible lesion of splenium of corpus callosum in a patient with colorectal cancer. BMJ Case Rep. 2017;2017:bcr2017222030. https:\/\/doi.org\/10.1136\/bcr-2017-222030.","journal-title":"BMJ Case Rep."},{"issue":"3","key":"4416_CR17","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00280-011-1666-0","volume":"68","author":"PY Cordier","year":"2011","unstructured":"Cordier PY, Nau A, Ciccolini J, et al. 5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases. Cancer Chemother Pharmacol. 2011;68(3):823\u20136. https:\/\/doi.org\/10.1007\/s00280-011-1666-0.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"4416_CR18","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1148\/rg.2017160085","volume":"37","author":"J Starkey","year":"2017","unstructured":"Starkey J, Kobayashi N, Numaguchi Y, Moritani T. Cytotoxic lesions of the corpus callosum that show restricted diffusion: mechanisms, causes, and manifestations. Radiographics. 2017;37(2):562\u201376. https:\/\/doi.org\/10.1148\/rg.2017160085.","journal-title":"Radiographics"},{"issue":"3","key":"4416_CR19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/CAD.0000000000000730","volume":"30","author":"A Boil\u00e8ve","year":"2019","unstructured":"Boil\u00e8ve A, Wicker C, Verret B, Leroy F, Malka D, Jozwiak M, et al. 5-fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathy. Anticancer Drugs. 2019;30(3):313\u20137. https:\/\/doi.org\/10.1097\/CAD.0000000000000730.","journal-title":"Anticancer Drugs"},{"issue":"7","key":"4416_CR20","first-page":"3277","volume":"17","author":"S Haghighi","year":"2016","unstructured":"Haghighi S, Kasbkar H, Esmaeilpour K, Yasaei M. Oxaliplatin, 5Fluorouracil and leucovorin (FOLFOX4) as first line chemotherapy in elderly patients with advanced gastric cancer. Asian Pac J Cancer Prev. 2016;17(7):3277\u201380. PMID: 27509963.","journal-title":"Asian Pac J Cancer Prev"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04416-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04416-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04416-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T12:03:54Z","timestamp":1764072234000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-025-04416-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4416"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04416-w","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"28 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Case reports are exempt from IRB review at our institution.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent obtained from relative of patient and will provide copy of consent on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"481"}}